Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.48 |
| ▸ | CNR1 | P21554 | 11/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21506172 | 0.91 | CNR2 (0.43) | CNR2CNR1SIGMAR1EGLN1FAAH | |
| SCHEMBL21506586 | 0.91 | CNR2 (0.43) | CNR2CNR1SIGMAR1EGLN1FAAH | |
| SCHEMBL21481825 | 0.90 | CNR2 (0.47) | CNR2CNR1EGLN1 | |
| SCHEMBL21506718 | 0.90 | CNR2 (0.46) | CNR2CNR1SIGMAR1CYP1A2CYP3A4 | |
| SCHEMBL21506741 | 0.89 | MEN1 (0.43) | CNR2CNR1EGLN1FAAHBRD4 | |
| SCHEMBL21482091 | 0.89 | PTGER4 (0.43) | CNR2CNR1SIGMAR1CYP1A2CYP3A4 | |
| SCHEMBL21481677 | 0.88 | CNR2 (0.41) | CNR2CNR1EGLN1 | |
| SCHEMBL21481619 | 0.87 | FFAR4 (0.41) | CNR2CNR1FAAH | |
| SCHEMBL21506544 | 0.87 | CNR1 (0.40) | CNR2CNR1SIGMAR1EGLN1FAAH | |
| SCHEMBL21506567 | 0.87 | CNR1 (0.40) | CNR2CNR1SIGMAR1EGLN1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | TEMPEST THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795156-B2 | Bicyclic carboxamides and methods of use thereof | PTGER4, PTGER2, CNR2 | CNR2 3/4885CNR1 6/4885SIGMAR1 539/4885 |
| US-20230045612-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CNR2 3/4885CNR1 6/4885SIGMAR1 539/4885 |
| US-20210024491-A1 | BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF | PTGER4, PTGER2, CNR2 | CNR2 3/4885CNR1 6/4885SIGMAR1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.